Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

SUMMARY: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Osteoporos Int
Autors principals: Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Format: Artigo
Idioma:Inglês
Publicat: Springer London 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://ncbi.nlm.nih.gov/pubmed/32935170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-020-05555-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars